Morgan Stanley has filed a free writing prospectus for BSX Jump Notes due December 5, 2029. This filing is notable as it showcases the company's ongoing efforts to diversify its financial product offerings. The new notes are linked to Boston Scientific Corporation common stock, which may attract investor interest in the current market.

The filing, dated November 4, 2026, indicates that the issuer of the notes is Morgan Stanley Finance LLC, with Morgan Stanley acting as the guarantor. The notes are designed to provide investors with potential upside payments based on the performance of the underlying stock.

Background

Morgan Stanley, a prominent player in the financial services industry, operates under the Standard Industrial Classification of 6211, which includes Security Brokers, Dealers & Flotation Companies. The firm is publicly traded on the New York Stock Exchange under the ticker symbol MS, among others. It has a long history of providing a range of financial services, including investment banking, wealth management, and asset management.

What the Filing Says

The filing includes a summary of the terms of the BSX Jump Notes, noting that they will not pay interest and have a fixed appreciation potential. The notes are expected to have an estimated value of approximately $971.10 per note, with an upside payment of $303.50 per note, contingent on the performance of the underlying stock.

Impact

This offering may affect a variety of stakeholders, including investors looking for alternative investment options and competitors in the financial services sector. The introduction of these notes could intensify competition among firms like Goldman Sachs and JPMorgan Chase, as they also seek to innovate and expand their product lines.

What's Next

The filing does not specify what happens next, but it is expected that Morgan Stanley will continue to provide additional information and updates related to this offering as it progresses.